Advanced Search
Submit Manuscript Volume 28, No 3, Mar 2018
ISSN: 1001-0602
EISSN: 1748-7838 2018
impact factor 17.848*
(Clarivate Analytics, 2019)
Volume 28 Issue 3, March 2018: 336-358
Qiang Wang1,2,*, Jun Jiang3,*, Guoguang Ying4,*, Xiao-Qing Xie1,2,*, Xia Zhang1,2, Wei Xu1,2,5, Xuemin Zhang6, Erwei Song7, Hong Bu8, Yi-Fang Ping1,2, Xiao-Hong Yao1,2, Bin Wang1,2, Shilei Xu4, Ze-Xuan Yan1,2,Yanhong Tai9,10, Baoquan Hu3, Xiaowei Qi3, Yan-Xia Wang1,2, Zhi-Cheng He1,2, Yan Wang1,2, Ji Ming Wang11, You-Hong Cui1,2, Feng Chen12, Kun Meng12, Zhaoyi Wang1,2,13, Xiu-Wu Bian1,2
1 Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing 400038, China; 2 Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Chongqing 400038, China; 3 Department of Breast Diseases, Southwest Cancer Center, Southwest Hospital, Third Military Medical University, Chongqing 400038, China; 4 Laboratory of Cancer Cell Biology, Tianjin Cancer Institute, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China; 5 McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, WI 53706, USA; 6 State Key Laboratory of Proteomics, Institute of Basic Medical Sciences, China National Center of Biomedical Analysis, Beijing 100850, China; 7 Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China; 8 Department of Pathology, West China Hospital, Sichuan University, Chengdu 610041, China; 9 Department of Pathology, General Hospital of PLA, Beijing 100853, China; 10Department of Pathology, No.307 Hospital of PLA, Beijing 100071, China; 11Laboratory of Molecular Immunoregulation, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA; 12Shenogen Pharma Group, Beijing 100085, China; 13Departments of Medical Microbiology & Immunology, Creighton University Medical School, 2500 California Plaza, Omaha, NE 68178, USA Correspondence: Xiu-Wu Bian, Tel: +86-23-68754431; Fax: +86-23-65397004(bianxiuwu@263.net)